Published in BJU Int on May 01, 2004
Antibody Microarray Analysis of Signaling Networks Regulated by Cxcl13 and Cxcr5 in Prostate Cancer. J Proteomics Bioinform (2012) 0.82
Transcription variants of the prostate-specific PrLZ gene and their interaction with 14-3-3 proteins. Biochem Biophys Res Commun (2009) 0.78
Exogenous p27KIP1 expression induces anti-tumour effects and inhibits the EGFR/PI3K/Akt signalling pathway in PC3 cells. Asian J Androl (2009) 0.76
Genes differentially expressed in prostate cancer. BJU Int (2004) 0.75
Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res (1994) 3.43
The efficacy of dihydrotestosterone transdermal gel before primary hypospadias surgery: a prospective, controlled, randomized study. J Urol (2007) 2.85
Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med (1993) 2.85
Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer (1999) 2.34
Detection of prostate cancer with a microbubble ultrasound contrast agent. Lancet (2001) 2.23
Prostaglandin E2 and tumor necrosis factor alpha cooperate to activate human dendritic cells: synergistic activation of interleukin 12 production. J Exp Med (1997) 2.14
Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. J Pathol (2000) 2.11
Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology (2001) 2.10
Evaluation and management of renal injuries: consensus statement of the renal trauma subcommittee. BJU Int (2004) 2.09
Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res (1998) 2.07
Urinary incontinence in the elderly and age-dependent apoptosis of rhabdosphincter cells. Lancet (1999) 1.92
Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol (1993) 1.73
Androgen receptors in prostate cancer. Endocr Relat Cancer (2002) 1.71
New onset hypertension after extracorporeal shock wave lithotripsy: age related incidence and prediction by intrarenal resistive index. J Urol (1997) 1.70
Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res (1995) 1.63
Neobladder emptying failure in males: incidence, etiology and therapeutic options. J Urol (2006) 1.61
Urethra-sparing cystectomy and orthotopic urinary diversion in women with malignant pelvic tumors. Cancer (2001) 1.58
Rapid signalling by androgen receptor in prostate cancer cells. Oncogene (1999) 1.54
Testicular torsion: late results with special regard to fertility and endocrine function. J Urol (1980) 1.52
Metastatic lesions from prostate cancer do not express oestrogen and progesterone receptors. J Pathol (1997) 1.52
Sildenafil modulates hemodynamics and pulmonary gas exchange. Am J Respir Crit Care Med (2001) 1.50
Laparoscopic surgery for pheochromocytoma: adrenalectomy, partial resection, excision of paragangliomas. J Urol (1998) 1.47
Zoledronic acid influences growth, migration and invasive activity of prostate cancer cells in vitro. Prostate Cancer Prostatic Dis (2012) 1.43
Regulation of prostatic growth and function by peptide growth factors. Prostate (1996) 1.42
Lich-Gregoir reimplantation causes less discomfort than Politano-Leadbetter technique: Results of a prospective, randomized, pain scale-oriented study in a pediatric population. Eur Urol (2005) 1.39
Extracorporeal shock wave lithotripsy versus ureteroscopy for distal ureteral calculi: a prospective randomized study. J Urol (1999) 1.33
Androgen receptor--an update of mechanisms of action in prostate cancer. Urol Res (2000) 1.25
Age, prostate-specific antigen, and digital rectal examination as determinants of the probability of having prostate cancer. Urology (2001) 1.24
The female urethral sphincter: a morphological and topographical study. J Urol (1998) 1.24
Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous testicular carcinoma: long-term outcome. J Urol (2000) 1.24
Radical prostatectomy: the value of preoperative, individually labeled apical biopsies. J Urol (2000) 1.23
Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Cancer Gene Ther (2000) 1.21
Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol (1999) 1.20
Treatment of giant ancient pelvic schwannoma. Tech Urol (2001) 1.20
Expression, structure, and function of androgen receptor in advanced prostatic carcinoma. Prostate (1998) 1.19
Bacillus Calmette-Guérin mycobacteria stimulate human blood dendritic cells. Int J Cancer (1997) 1.19
Posttraumatic posterior urethral stricture repair: anatomy, surgical approach and long-term results. J Urol (1997) 1.19
Guidelines for the diagnosis and treatment of benign prostatic hyperplasia: a comparative, international overview. Urology (2001) 1.18
Laparoscopic nephron sparing surgery for small renal cell carcinoma. J Urol (1998) 1.17
Androgen receptor-Ets protein interaction is a novel mechanism for steroid hormone-mediated down-modulation of matrix metalloproteinase expression. J Biol Chem (1996) 1.16
Androgen receptor status of lymph node metastases from prostate cancer. Prostate (1996) 1.16
Crossing vessels at the ureteropelvic junction: detection with contrast-enhanced color Doppler imaging. Radiology (1999) 1.16
Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. Clin Cancer Res (2001) 1.13
Transurethral prostatectomy: mortality and morbidity. Prostate (1996) 1.13
Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. World J Urol (2002) 1.13
Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. Eur Urol (2000) 1.12
Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer. Prostate (2000) 1.12
Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer. Prostate Cancer Prostatic Dis (2013) 1.11
Isolated right-sided varicocele as a salvage pathway for portal hypertension. Int J Clin Pract (2005) 1.08
Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia. J Urol (1979) 1.08
Primary lymphatic metastatic spread in testicular cancer occurs ventral to the lumbar vessels. Urology (2002) 1.07
Morphometry in experimental pathology: methods, baseline data and applications. Int Rev Exp Pathol (1976) 1.07
Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer. Prostate Cancer Prostatic Dis (2004) 1.07
Comparison of contrast enhanced color Doppler targeted biopsy to conventional systematic biopsy: impact on Gleason score. J Urol (2007) 1.07
Laparoscopic partial adrenalectomy in patients with aldosterone-producing adenomas: indications, technique, and results. Urology (2003) 1.06
Transforming growth factors-beta 1 and beta 2 in serum and urine from patients with bladder carcinoma. J Urol (1996) 1.05
Orgotein: a new antiinflammatory metalloprotein drug evaluation of clinical efficacy and safety in inflammatory conditions of the urinary tract. Int Urol Nephrol (1974) 1.04
Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours. Endocr Relat Cancer (2005) 1.02
Age dependent apoptosis and loss of rhabdosphincter cells. J Urol (2000) 1.01
DNA sequence of the androgen receptor in prostatic tumor cell lines and tissue specimens assessed by means of the polymerase chain reaction. Prostate (1993) 1.01
Molecular biology of the androgen receptor: from molecular understanding to the clinic. Eur Urol (2001) 1.01
Androgen signal transduction and prostatic carcinoma. World J Urol (1994) 1.00
Quality of life after cystectomy and orthotopic neobladder versus ileal conduit urinary diversion. World J Urol (2000) 1.00
Management of benign prostatic hyperplasia with particular emphasis on aromatase inhibitors. J Steroid Biochem Mol Biol (1993) 1.00
Upgrading of Gleason score 6 prostate cancers on biopsy after prostatectomy in the low and intermediate tPSA range. Prostate Cancer Prostatic Dis (2009) 0.99
Changing diagnostic and therapeutic concepts in high-flow priapism. Int J Impot Res (2005) 0.99
Laparoscopic and retroperitoneoscopic repair of ureteropelvic junction obstruction. Urology (1996) 0.98
Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. Eur Urol (1995) 0.98
Anatomic and functional studies of the male and female urethral sphincter. World J Urol (2000) 0.97
Point mutation in the DNA binding domain of the androgen receptor in two families with Reifenstein syndrome. Am J Hum Genet (1992) 0.96